Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Buy and lowers the price target from $33 to $32.